<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01565681</url>
  </required_header>
  <id_info>
    <org_study_id>7163-CL-0101</org_study_id>
    <nct_id>NCT01565681</nct_id>
  </id_info>
  <brief_title>Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects</brief_title>
  <official_title>A Phase 1 Single Ascending Dose Study of ASKP1240 in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety, tolerability, pharmacodynamics and
      pharmacokinetics of ASKP1240 after a single intravenous dose at escalating dose levels in
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic variable: Individual subject cell surface antigen (CD40) occupancy levels over time</measure>
    <time_frame>Days 1-3, 5, 8,15, 22, 29, 43, 60, 75, and 90</time_frame>
    <description>binding of ASKP1240-biotin to B cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics profile: AUCinf and Cmax</measure>
    <time_frame>Days 1-8,15, 22, 29, 43 and 60</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf) and Maximum concentration of study drug (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics profile: AUClast, tmax, t1/2, Vz, and CLtot</measure>
    <time_frame>Days 1-8,15, 22, 29, 43 and 60</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 up to the last quantifiable concentration (AUClast),Time to attain Cmax (tmax), Apparent terminal elimination of half-life (t1/2), Apparent volume of distribution ( Vz), and Total body clearance (CLtot)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lymphocyte count</measure>
    <time_frame>Day -1, Days 1-3, 5, 8,15, 22, 29, 43, and 60</time_frame>
    <description>product of the white blood count (WBC) and percent lymphocytes [from differential]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral lymphocyte subset quantification</measure>
    <time_frame>Day -1, Days 1-3, 5, 8,15, 22, 29, 43, and 60</time_frame>
    <description>leukocycte phenotypes: CD3, CD4, CD8,CD16, and CD20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs), physical examination, pulse oximetry, and incidence of anti-ASKP1240 antibody formation</measure>
    <time_frame>Up to day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Pharmacokinetics of ASKP1240</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Arm A: ASKP1240 lowest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: ASKP1240 second lowest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: ASKP1240 third lowest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: ASKP1240 fourth lowest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E: ASKP1240 fifth lowest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F: ASKP1240 middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G: ASKP1240 sixth highest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm H: ASKP1240 fifth highest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I: ASKP1240 fourth highest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm J: ASKP1240 third highest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm K: ASKP1240 second highest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm L: ASKP1240 highest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm M: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1240</intervention_name>
    <description>infusion</description>
    <arm_group_label>Arm A: ASKP1240 lowest dose</arm_group_label>
    <arm_group_label>Arm B: ASKP1240 second lowest dose</arm_group_label>
    <arm_group_label>Arm C: ASKP1240 third lowest dose</arm_group_label>
    <arm_group_label>Arm D: ASKP1240 fourth lowest dose</arm_group_label>
    <arm_group_label>Arm E: ASKP1240 fifth lowest dose</arm_group_label>
    <arm_group_label>Arm F: ASKP1240 middle dose</arm_group_label>
    <arm_group_label>Arm G: ASKP1240 sixth highest dose</arm_group_label>
    <arm_group_label>Arm H: ASKP1240 fifth highest dose</arm_group_label>
    <arm_group_label>Arm I: ASKP1240 fourth highest dose</arm_group_label>
    <arm_group_label>Arm J: ASKP1240 third highest dose</arm_group_label>
    <arm_group_label>Arm K: ASKP1240 second highest dose</arm_group_label>
    <arm_group_label>Arm L: ASKP1240 highest dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>infusion</description>
    <arm_group_label>Arm M: Placebo</arm_group_label>
    <other_name>Sodium Chloride solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject weighs at least 50 kg, and has a body mass index (BMI) of 18 to 32 kg/m2
             inclusive

          -  The female subject must be of non-childbearing potential (surgically sterile
             [hysterectomy or bilateral tubal ligation] or post-menopausal â‰¥ 1 year with follicle
             stimulating hormone [FSH] &gt; 40 U/L)

          -  Male subject agrees to no sperm donation until end of study or 90 days post dose,
             whichever is longer

          -  The subject is highly likely to comply with the protocol and complete the study

          -  The subject has a negative urine screen for drugs of abuse, and negative blood or
             breathalyzer alcohol screen at Screening and clinic admission on Day 1

        Exclusion Criteria:

          -  The subject has a history of severe allergic or anaphylactic reactions

          -  The subject has history of consuming more than 14 units of alcoholic beverages per
             week or has a history of alcoholism or drug/chemical/substance abuse within past 2
             years prior to screening (Note: one unit = 12 ounces of beer, 4 ounces of wine or 1
             ounce of spirits)

          -  The subject has/had a symptomatic, viral, bacterial (including upper respiratory
             infection), or fungal (non-cutaneous) infection within 1 week prior to clinic check in

          -  The subject has a supine mean systolic blood pressure &lt; 90 or &gt; 160 mmHg and a mean
             diastolic blood pressure &lt; 50 or &gt; 90 mmHg, or pulse rate higher than 100 beats per
             min (bpm), either at screening or clinic check in (blood pressure measurements taken
             in triplicate after subject has been resting in a supine position for a minimum of 5
             minutes)

          -  The subject is known positive for human immunodeficiency virus (HIV) antibody

          -  The subject has a positive test for hepatitis C antibody, or for hepatitis B virus
             surface antigen (HBsAg)

          -  The subject has at screening or clinic check in that:

               1. white blood cell count (WBC) is &lt; 3.5 or &gt; upper limit of normal

               2. absolute neutrophil count (ANC) is &lt;1.5 or &gt; upper limit of normal

               3. platelet count (PLT) is outside the normal limit

               4. serum creatinine, total bilirubin, alanine aminotransferase (ALT), or aspartate
                  aminotransferase (AST) are &gt; upper limit of normal

               5. creatine phosphokinase (CPK) is &gt; two times upper limit of normal

               6. international normalized ratio (INR) is &gt; upper limit of normal

               7. OR remaining laboratory tests are outside the normal limits and considered by the
                  investigator to be clinically significant with regard to the remaining per
                  protocol laboratory tests

          -  The subject has received a vaccine within 60 days prior to study drug administration

          -  The subject has received any systemic immunosuppressant agent within 6 months prior to
             study drug administration.

          -  The subject has received any antibody or biologic product within 6 months prior to
             study drug administration

          -  The subject has received any systemic steroid within 2 months prior to study drug
             administration

          -  The subject has had treatment with prescription or non-prescription drugs, including
             complementary and alternative medicines (CAM) and excluding over-the-counter (OTC)
             allergy medications, nasal steroids, nasal inhalers, oral contraceptives, stable
             hormone replacement therapy (HRT; per Investigator judgment and dose change not
             expected during study), and intermittent acetaminophen, within 14 days prior to study
             drug administration

          -  The subject has received an experimental agent within 30 days or ten half-lives,
             whichever is longer, prior to study drug administration

          -  The subject is participating in another clinical trial or has participated in another
             dose group of the current trial

          -  The subject has donated or has had significant blood loss or received a transfusion of
             any blood or blood products within 60 days or donated plasma within 7 days prior to
             dosing

          -  The subject has a history of heavy smoking or has used tobacco-containing products and
             nicotine or nicotine-containing products in the past six months prior to Screening

          -  The subject has a history of thromboembolic or vascular disease especially deep vein
             thrombosis, pulmonary embolism and varices

          -  The subject has a positive test for tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2012</study_first_posted>
  <last_update_submitted>December 7, 2012</last_update_submitted>
  <last_update_submitted_qc>December 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <keyword>B cell CD40 receptor occupancy</keyword>
  <keyword>anti-CD40 monoclonal antibody</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

